The potential role of sunitinib in gastrointestinal cancers other than GIST.

Simple item page
dc.contributor.authorGrávalos, Cristina
dc.contributor.authorGrande-Pulido, E.
dc.contributor.authorGasent, Joan Manel
dc.date.accessioned2024-01-24T11:19:08Z
dc.date.available2024-01-24T11:19:08Z
dc.date.issued2010
dc.description.abstractGastrointestinal tumors are the most frequent and lethal malignancies worldwide. The deeper knowledge in molecular biology mechanisms involved in carcinogenesis has allowed the design of new targeted drugs mainly directed against the epidermal growth factor receptor (EGFR), the vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). Sunitinib is an oral multitargeted inhibitor of the VEGF, platelet-derived growth factor (PDGF), and c-KIT, among others, tyrosine kinase receptors. Therefore, sunitinib acts in a dual mode as antiangiogenic agent and as antitumoral drug. The aim of this review is to gather the preclinical rationale behind the clinical use of sunitinib in gastrointestinal malignancies other than gastrointestinal stromal tumors (GIST) and to summarize the clinical data from phase I to III trials currently available.spa
dc.identifier.doi10.1016/j.critrevonc.2010.01.008spa
dc.identifier.issn1040-8428spa
dc.identifier.urihttps://hdl.handle.net/10641/3813
dc.language.isoengspa
dc.publisherCritical Reviews in Oncology/Hematologyspa
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/abs/pii/S1040842810000090?via%3Dihubspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.accessRightsmetadata only accessspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.titleThe potential role of sunitinib in gastrointestinal cancers other than GIST.spa
dc.typejournal articlespa
dc.type.hasVersionSMURspa
dspace.entity.typePublication

Files

Collections

MEDICINA